THT 2024: CCM® Therapy in Addition to GDMT: Optimizing Strategy for Heart Failure
This session from THT 2024 will explain what Cardiac Contractility Modulation therapy is, how it works, and the expected outcomes when utilizing this treatment for HF in NYHA Class III patients who remain symptomatic despite guideline-directed medical therapy. Dr. Javed Butler discusses the challenges that continue to exist in the treatment of heart failure and the unmet needs the provider community must face together. (0:00 – 9:45) Dr. Niraj Varma introduces the Integra D Trial design and inclusion criteria. CCM-D is an investigational device in clinical trials that has both CCM and defibrillator capabilities. (9:46 – 22:07) Dr. Rami Kahwash talks about his experiences with CCM® therapy and approaches to identify appropriate candidates in patients with limited options available to improve their symptoms and quality of life. He presents his personal experience with a case study. (22:08 – 37:40) Finally, the panel addresses questions and provides answers. (37:41 – 54:47)
THT 2024: Heart Failure Management Today – GDMT, CRT, and CCM® Therapy
THT 2024: Update on the Integra-D Trial - CCM® Therapy
THT 2024: CCM® Therapy - Don’t Wait!
THT 2024: Heart Failure Management Today – GDMT, CRT, and CCM® Therapy
THT 2024: Update on the Integra-D Trial - CCM® Therapy
THT 2024: CCM® Therapy - Don’t Wait!
Comments 0
Login to view comments.
Click here to Login
